Beta Bionics Inc. (BBNX) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 15 wire items for BBNX, including 4 insider trades, 3 press releases and news items and 3 market updates. The most recent was published Nov 3, 2026.
BBNX rankings
Financial highlights
Full financials- Revenue, TTM
- $127.27M
- Revenue growth
- +43.7%
- Net income, TTM
- -$83.12M
- Net margin
- -65.3%
- Free cash flow, TTM
- -$65.96M
- Cash
- $81.55M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks69-45%
2026-05-102026-11-01
Mix4090d
- Insider16(40%)
- Other8(20%)
- SEC Filings5(13%)
- Analyst4(10%)
- Offering4(10%)
- Market3(8%)
Latest news
25 items- PRBeta Bionics Announces Participation at Upcoming Investor ConferencesIRVINE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will participate at upcoming investor conferences: Members of the Company’s management team will present at the Wolfe Research 8th Annual Healthcare Conference on Tuesday, November 10, 2026 at 12:40pm Eastern Time.Members of the Company’s management team will present at the Stifel 2026 Healthcare Conference on Wednesday, November 11, 2026 at 8:40am Eastern Time.Members of the Company’s management team will attend the Jefferies 2026 Global Healthcare Conference in London and host in-person meeti
- NEWSBBNX UPCOMING DEADLINE: Levi & Korsinsky Alerts Beta Bionics, Inc. Stockholders of Securities Class Action - Contact the FirmNEW YORK CITY, NY / ACCESS Newswire / October 30, 2026 / Levi & Korsinsky, LLP alerts investors in Beta Bionics, Inc. (NASDAQ:BBNX) that a securities class action was filed on behalf of shareholders who purchased securities between July 30, 2025 and February 24, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.BBNX traded at $31.99 per share on January 8, 2026. By April 10, 2026, the stock closed under $9, roughly $23.09 per share below that level, a decline of approximately 72% that erased hundreds of millions of dollars in market capitalization. Investors have until November 3, 2026 to seek appointme
- INSIDERChief Product Officer Mensinger Mike sold $58,300 worth of shares (2,650 units at $22.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Commercial Officer Hopman Mark sold $16,420 worth of shares (821 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- SECSEC Form 10-Q filed by Beta Bionics Inc.10-Q - Beta Bionics, Inc. (0001674632) (Filer)
- SECSEC Form 8-K filed by Beta Bionics Inc.8-K - Beta Bionics, Inc. (0001674632) (Filer)
- PRBeta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 GuidanceIRVINE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2026 and updated its full year guidance for the year ending December 31, 2026. Third Quarter 2026 Financial Highlights & Key Metrics Net sales of $35.5 million, up 30% compared to $27.3 million in the third quarter of 2025. Durable Medical Equipment (DME) channel net sales of $21.9 million, up 4% compared to $21.0 million in the third quarter of 2025.Pharmacy Benefit Plan (PBP) channel net sales of $13.6 million, up 118% compared to $6.2 million in the
- PRINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Beta Bionics, Inc. to Contact Law FirmBeta Bionics, Inc. (NASDAQ:BBNX) shareholders should email fletcher@fmoorelaw.comNEW YORK, Oct. 19, 2026 /PRNewswire/ -- What is the Investigation About?On January 8, 2026, after the market closed, Beta Bionics reported an unexpected shortfall in new patient starts for its iLet Bionic Pancreas insulin pump. This announcement followed a December 2025 report by The Capitol Forum that made public an FDA Form 483 concerning the device.Following this news, the price of Beta Bionics stock fell $11.85 per share, or approximately 37%, to close at $20.14 per share on January 9, 2026.On January 30, 2026, Beta Bionics disclosed that the F
- INSIDERChief Commercial Officer Hopman Mark sold $13,446 worth of shares (775 units at $17.35) (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- NEWSBBNX DEADLINE: Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of Upcoming Securities Class Action DeadlineNotice to Pension Funds, Asset Managers, and Fiduciaries NEW YORK CITY, NY / ACCESS Newswire / October 16, 2026 / Levi & Korsinsky, LLP notifies institutional investors in Beta Bionics, Inc. (NASDAQ:BBNX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between July 30, 2025 and February 24, 2026. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.BBNX declined from a Class Period high of $31.99 to under $9.00 by April 10, 2026, a drop of approximately $23.09 per share, or 72%. Hundreds of millions of dollars in market capitalization were erased across the
- ANALYSTJefferies initiated coverage on Beta Bionics with a new price targetJefferies initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $30.00
- NEWSBBNX Investor Alert: Beta Bionics, Inc. Securities Class Action Notice - Contact Levi & KorsinskyNEW YORK CITY, NY / ACCESS Newswire / October 9, 2026 / Levi & Korsinsky, LLP reminds purchasers of Beta Bionics, Inc. (NASDAQ:BBNX) securities that a class action is pending on behalf of shareholders who acquired shares between July 30, 2025 and February 24, 2026. See if you could be eligible to recover. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.From a Class Period high of $31.99 on January 8, 2026, BBNX shares fell to approximately $8.90 by April 10, 2026, a decline of $23.09 per share, or roughly 72%. The steepest single session took shares down 37%, or $11.85, to close at $20.14. Investors have until November 3, 2026 to seek lead plaintiff sta
- SECSEC Form SCHEDULE 13G filed by Beta Bionics Inc.SCHEDULE 13G - Beta Bionics, Inc. (0001674632) (Subject)
- ANALYSTBarclays initiated coverage on Beta Bionics with a new price targetBarclays initiated coverage of Beta Bionics with a rating of Overweight and set a new price target of $30.00
- INSIDERChief Commercial Officer Hopman Mark sold $7,015 worth of shares (370 units at $18.96) (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- PRBeta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quarter 2026 financial results after the financial markets close on Tuesday, October 27, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s third quarter 2026 performance. The link to the webcast will be available on the Company’s website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. T
- INSIDERDirector Jones Christy sold $147,890 worth of shares (6,430 units at $23.00) as part of a pre-agreed trading plan, decreasing direct ownership by 25% to 19,564 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- ANALYSTWells Fargo initiated coverage on Beta Bionics with a new price targetWells Fargo initiated coverage of Beta Bionics with a rating of Overweight and set a new price target of $28.00
- PRBeta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery (AID) systems with Senseonics’ Eversense 365 continuous glucose monitoring (CGM) system. Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, at which time Beta Bionics expects iLet to support the most CGM manufacturer options of any AID system, maximizing choice for its users. The companies have also committed to the integration of mint and Eversense 365 in the futu
- INSIDERAmendment: Chief Commercial Officer Hopman Mark sold $664,550 worth of shares (35,994 units at $18.46) as part of a pre-agreed trading plan, decreasing direct ownership by 29% to 88,033 units (SEC Form 4)4/A - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Commercial Officer Hopman Mark sold $619,640 worth of shares (30,779 units at $20.13) as part of a pre-agreed trading plan, decreasing direct ownership by 35% to 56,479 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Product Officer Mensinger Mike sold $58,300 worth of shares (2,650 units at $22.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 177,390 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- PRBeta Bionics Announces Closing of $172.5 Million Public Offering of Common StockIRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per share, which equals the public offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. In addition, the underwriters exercised their option in full and purchased 1,304,348 additional shares of common stock. Including the op
- SECSEC Form 424B5 filed by Beta Bionics Inc.424B5 - Beta Bionics, Inc. (0001674632) (Filer)
- SECSEC Form FWP filed by Beta Bionics Inc.FWP - Beta Bionics, Inc. (0001674632) (Subject)
BBNX FAQ
10 questionsWhat is the latest news on BBNX?
In the last 30 days Quantisnow tracked 15 wire items for BBNX: 4 insider trades, 3 press releases and news items, 3 market updates and 2 analyst ratings. The most recent was published on November 3, 2026.What is BBNX revenue?
Beta Bionics Inc. (BBNX) reported $127.27M of revenue for the twelve months ended Sep 30, 2026. That is up 43.7% from the year before. Revenue for fiscal 2025 was $100.25M.Is BBNX profitable?
No. Beta Bionics Inc. reported a net loss of $83.12M for the twelve months ended Sep 30, 2026.How much cash and debt does BBNX have?
Beta Bionics Inc. reported $81.55M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does BBNX stock trade?
Beta Bionics Inc. (BBNX) is listed on NASDAQ.What sector and industry is BBNX in?
Beta Bionics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Beta Bionics Inc. go public?
Beta Bionics Inc. (BBNX) completed its IPO in 2025.What are analysts saying about BBNX?
Across the last 8 analyst actions on Beta Bionics Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Jefferies: Buy with a $30.00 price target on 2026-10-12. Recent price targets range from $17.00 to $30.00.What companies are similar to BBNX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare BBNX side-by-side with any of them on Quantisnow.How can I track BBNX on Quantisnow?
Quantisnow aggregates Beta Bionics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BBNX to receive live email and push alerts on every new disclosure.